entertainment -WSS

entertainment

author：fashion 2025-10-01 11:46:50 - browse：5

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

knowledge

WSS

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

FTC loses bid to block Novant's North Carolina hospital merger

BD to buy Edwards patient monitoring unit for $4.2 billion

340B reform proposal comes out of Senate working group

Unique patient identifier: Experts argue the benefits, pitfalls

Medicare Advantage's lean provider networks lead CMS complaints

leisure time

entertainment

hotspot

In Memoriam: Notable people who died in 2023

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Affirmative action in medical school literally saved lives

Global cancer cases to surge 77% by 2050, WHO report says

In Memoriam: Notable people who died in 2023

Bernie brings in new pharma CEOs to talk drug prices

Supreme Court strikes down use of affirmative action

Updated Covid vaccine has 54% effectiveness, new study suggests

Supreme Court strikes down use of affirmative action

Eli Lilly’s Zepbound improved liver scarring in mid

focus

Problems with a popular proposal to regulate AI in health care

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Adopting new red light myopia treatments may be short

Finland to offer bird flu vaccine to select groups of people, a possible global first

Johnson & Johnson sued for allegedly overpaying for workers' drugs

FTC loses bid to block Novant's North Carolina hospital merger

leisure time

leisure time

knowledge

knowledge